Voxelotor - Global Blood Therapeutics
Alternative Names: GBT-440; GTx-011; OxbrytaLatest Information Update: 01 Oct 2024
At a glance
- Originator Global Blood Therapeutics
- Developer Global Blood Therapeutics; Pfizer
- Class Antianaemics; Antifibrotics; Benzaldehydes; Ethers; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Sickle haemoglobin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Sickle cell anaemia
- Discontinued Hypoxia; Idiopathic pulmonary fibrosis
Most Recent Events
- 01 Oct 2024 Withdrawn for Sickle cell anaemia (In children, In the elderly, In adults, In adolescents) in United Arab Emirates (PO)
- 25 Sep 2024 Discontinued - Clinical-Phase-Unknown for Sickle cell anaemia (In the elderly, In adults, In adolescents) in Brazil (PO)
- 25 Sep 2024 Discontinued - Phase-II for Sickle cell anaemia (In adolescents, In infants) in USA (PO)